CircRNA_100395 protects breast carcinoma deterioration by targeting MAPK6.

OBJECTIVE: This study aims to uncover the differential expression of circRNA_100395 in breast carcinoma specimens, and its regulatory effect on cancer cell phenotypes. The role of circRNA_100395 in affecting breast carcinoma progression and the molecular mechanism are explored as well. PATIENTS AND METHODS: CircRNA_100395 expressions in breast carcinoma and paracancerous tissues were detected. The influence of circRNA_100395 level on clinical indicators of breast carcinoma patients was analyzed. In vitro regulations of circRNA_100395 on phenotypes of breast carcinoma cells were examined by CCK-8, colony formation, and transwell assay. The interaction between circRNA_100395 and MAPK6 was confirmed by Dual-Luciferase reporter assay and rescue assays. RESULTS: CircRNA_100395 was downregulated in breast carcinoma tissues and cell lines. Its level was negatively correlated to tumor staging and tumor size of breast carcinoma. Overexpression of circRNA_100395 in SKBR3 and MDA-MB-231 cells weakened proliferative and migratory abilities. MAPK6 was the target gene of circRNA_100395. Overexpression of MAPK6 reversed the anti-cancer effect of circRNA_100395 on breast carcinoma. CONCLUSIONS: CircRNA_100395 serves as an anti-cancer gene in breast carcinoma progression by targeting MAPK6, and its level is negatively correlated to tumor staging and tumor size of breast carcinoma. CircRNA_100395 can be utilized as a potential biomarker and therapeutic target of breast carcinoma.

Synthesis and antinociceptive activity of capsinoid derivatives.

According to the data of structural identification, six capsinoids or their derivatives were successfully synthesized to test for their analgesic activity. Three of them were capsinoids with different acyl chain compared with capsaicin after substitution of ester for amide at C(1) position. The other three could be described as capsinoid derivatives with different alkoxy chain, compared with capsaicin after substitution of ester for amide at C(1) position and alkoxy for hydroxy at C(4) position and synthesis of them was reported first. Compared with capsaicin, experiment results about pungency showed that capsinoids and their derivatives synthesized were all no or only slight pungent; that is, capsinoid derivates synthesized still have the same advantage of nonpungency with capsinoid. Relation between analgesic activity and molecular structure of compounds synthesized was also reported first, which would facilitate finding capsinoid derivatives owning excellent analgesic activity. The experiment results about analgesic activity showed that capsinoids displayed moderate analgesia effect and their antinociceptive activity decreased with the elongation of acyl chain at C(1) position; that antinociceptive activities of capsinoid derivatives synthesized were much stronger not only than those of indomethacin but also than those of their precursor (vanillyl decanoate), which increased with elongation of alkoxyl chain at C(4) position. Especially 4-hexyloxyl-3-methoxybenzyl decanoate showed the best antinociceptive activity in synthesized compounds, which was 9-fold higher than its precursor (vanillyl decanoate) and 6-fold higher than that of indomethacin.

[A comparative study of rifapentine treatment and three years follow-up on initial pulmonary tuberculous].

A clinical study about the efficacy of rifapentine in the treatment and 3 years' follow up on initial pulmonary tuberculous patient. Altogether 267 patients of initial pulmonary tuberculosis with positive smears were randomly divided into 3 groups; Group I with DL473 twice-weekly (2HE+L2/7H2L2), Group IIARFp twice-weekly (2HE+R2/7H2R2) and Group IIBRFP daily (2HRE/7HR) for controls. Results are: the conversion rate to smear negative are 96.0%, 96.4% and 97.1% respectively (P > 0.05); the sputum conversion rate by cultures are 98.0%, 95.7% and 96.4% respectively (P > 0.05). From X-Ray pictures, the treatment effect of Group I are similar to that of Group IIB. But in Group I with less side action were observed. The relapse rate of the three groups are 2.6%, 3.8% and 3.1% respectively (P > 0.05). From this investigation, we can draw a conclusion that the twice-weekly of rifapentine has at least an effect similar to rifampicin given daily. Further investigation of DL473 once weekly will soon be followed.